[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603356":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":25,"locations":31,"responsibleParty":51,"collaborators":54,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":66,"sex":67,"minAge":68,"maxAge":24,"enrollmentInfo":69,"targetDuration":24,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":24,"overallStatus":33,"whyStopped":24,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"University of Alabama at Birmingham","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"PCV20","EXPERIMENTAL","Will receive PCV20",[13],"Biological: Pneumococcal Vaccine",{"label":15,"type":10,"description":16,"interventionNames":17},"PCV21","Will receive PCV21",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"BIOLOGICAL","Pneumococcal Vaccine","PCV",[9,15],null,[26],{"name":27,"role":28,"phone":29,"phoneExt":24,"email":30},"David LaFon, MD","CONTACT","2059343411","dlafon@uabmc.edu",[32],{"facility":5,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"RECRUITING","Birmingham","Alabama","35294","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-86.80249,33.52066,{"lat":43,"lon":42},[46,48],{"name":47,"role":28,"phone":29,"phoneExt":24,"email":30},"LaFon, MD",{"name":49,"role":50,"phone":24,"phoneExt":24,"email":24},"David C LaFon, MD","PRINCIPAL_INVESTIGATOR",{"type":50,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"David Lafon","Assistant Professor",[55],{"name":56,"class":57},"Merck Sharp & Dohme LLC","INDUSTRY","100603356","phase-4-induction-of-cross-protective-antibodies-for-serogroup-33-by-pneumococcal-conjugate-vaccines-100603356",false,"NCT07135453","Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines","Novel Serotype Alert: Investigate New Pneumococcal Conjugate Vaccines for Inducing Cross-protection Against Newly Discovered Serotype 33E and Putative Novel Serogroup 33 Serotypes","Group 33\u002FPCVs","Inclusion Criteria:\n\n* Healthy adult\n\nExclusion Criteria:\n\n* No prior history of pneumococcal vaccination\n* No immunosuppressing medications or chronic diseases that affect immune function",true,"ALL","18 Years",{"count":70,"type":71},70,"ESTIMATED","INTERVENTIONAL",[74],"PHASE4","The goal of this study is to learn whether different types of vaccines to prevent bacterial infections are able to effectively create antibodies that defend against certain types of bacteria.\n\nWe will give two different types of vaccine and evaluate the effectiveness of antibodies produced by each vaccine in killing bacteria.",[77,78],"Vaccine","Pneumococcal Disease","2026-05-04",{"date":81,"type":82},"2026-05-05","ACTUAL",{"date":84,"type":71},"2026-05",{"date":86,"type":71},"2027-08",{"name":5,"class":6},1]